Novo Nordisk's Ozempic outperforms Lilly's Mounjaro on cardiovascular risk

Novo Nordisk's Ozempic outperforms Lilly's Mounjaro on cardiovascular risk: the analysis positions NVO, HIMS and ELV to benefit and LLY, VKTX and GPCR under pressure; confidence high.

Analyzed 2026-09-30 — point-in-time, never revised. Outcomes are scored against SPY and published either way.

Ranked exposures

1. ▲ NVO Novo Nordisk — impact +88 · confidence high · horizon immediate · 1st order
   Superior cardiovascular outcomes strengthen Ozempic’s formulary position, steering high risk patients toward Novo Nordisk and expanding market share.
   Chain: head to head cardiovascular data favors semaglutide → payers rank Ozempic ahead of Mounjaro → cardiologists and endocrinologists shift new starts → Novo captures larger incretin prescription share
   What would break the call: Supply constraints cap semaglutide units, so share gains fail to convert into revenue growth.
2. ▼ LLY Eli Lilly — impact -85 · confidence high · horizon immediate · 1st order
   Inferior cardiovascular results weaken Mounjaro and Zepbound formulary preference, shifting patients to Ozempic and reducing Eli Lilly sales.
   Chain: comparative cardiovascular data disadvantages tirzepatide → payer formularies demote Mounjaro and Zepbound → prescribers switch high risk patients away → Lilly incretin revenue growth decelerates
   What would break the call: Lilly's own outcomes trial reads out positive, restoring parity and formulary status.
3. ▼ VKTX Viking Therapeutics — impact -50 · confidence medium · horizon weeks · 2nd order
   Ozempic’s superior cardiovascular evidence raises Viking’s differentiation hurdle, weakening projected revenue and licensing economics.
   Chain: semaglutide sets higher cardiovascular efficacy benchmark → payers demand outcomes data from newcomers → Viking must run longer costly trials → partnering value and launch economics decline
   What would break the call: A large partner licenses VK2735 on rich upfront terms despite the new benchmark.
4. ▲ HIMS Hims & Hers — impact +48 · confidence low · horizon weeks · 2nd order
   Hims & Hers sells semaglutide-based weight programs, so demand shifts toward its platform and lifts subscription revenue.
   Chain: patients prefer semaglutide after outcomes data → Hims markets semaglutide based weight programs → subscriber additions and retention improve → subscription revenue per user rises
   What would break the call: Novo terminates the Hims supply arrangement or regulators curb compounded semaglutide sales.
5. ▼ GPCR Structure Therapeutics — impact -42 · confidence low · horizon quarters · 2nd order
   Structure Therapeutics must fund cardiovascular outcome studies for its oral candidate, pushing spending up and approval further out.
   Chain: injectable semaglutide proves cardiovascular benefit → payers require outcomes evidence for orals → Structure adds large cardiovascular trial → cash burn rises and timelines extend
   What would break the call: Regulators approve oral GLP-1 agents on weight endpoints alone without outcomes data.
6. ▲ ELV Elevance Health — impact +40 · confidence low · horizon quarters · 2nd order
   Elevance Health margins improve when cardiovascular events decrease among members prescribed Ozempic instead.
   Chain: members with cardiac risk receive semaglutide → heart attacks and strokes decline → inpatient and specialty claims fall → medical loss ratio improves
   What would break the call: GLP-1 pharmacy spend rises faster than avoided cardiac claims, widening the loss ratio.
7. ▼ ALT Altimmune — impact -38 · confidence low · horizon weeks · 3rd order
   Altimmune competes for scarce obesity trial funding, and an entrenched cardiovascular leader narrows the opening for pemvidutide.
   Chain: semaglutide entrenches as cardiovascular standard → investor capital rotates to proven assets → Altimmune faces tougher financing terms → pemvidutide development pace and value slip
   What would break the call: Pemvidutide liver disease data drives a partnership that funds development independently.
8. ▲ CVS CVS Health — impact +38 · confidence low · horizon quarters · 2nd order
   Caremark formularies already favor Wegovy, which strengthens rebate negotiating leverage and drives higher dispensing volume at CVS pharmacies.
   Chain: semaglutide wins preferred clinical standing → Caremark formularies already favor Wegovy → rebate leverage and script volume rise → pharmacy and PBM revenue increase
   What would break the call: Caremark reopens the formulary to tirzepatide, eroding the exclusive rebate advantage.
9. ▼ HCA HCA Healthcare — impact -35 · confidence low · horizon quarters · 3rd order
   HCA Healthcare revenue falls as fewer cardiovascular incidents reduce demand for related medical procedures.
   Chain: broad semaglutide use reduces cardiac events → fewer admissions for heart attack and stroke → cardiology procedure volumes decline slowly → hospital revenue growth moderates
   What would break the call: Hospital cardiac volumes keep rising as aging demographics outweigh drug driven risk reduction.
10. ▲ WST West Pharmaceutical Services — impact +35 · confidence low · horizon quarters · 2nd order
    West Pharmaceutical supplies elastomer components and syringe parts for semaglutide pens, so rising Novo output raises unit shipments.
    Chain: Novo raises semaglutide pen output → demand for elastomer stoppers and plungers rises → West ships more high value components → proprietary products revenue accelerates
    What would break the call: Novo destocks components after prior overbuild, cutting West orders despite higher end demand.
11. ▲ UNH UnitedHealth — impact +32 · confidence medium · horizon quarters · 2nd order
    Superior cardiovascular outcomes reduce heart attacks and strokes among UnitedHealth members, lowering medical costs across its insurance book.
    Chain: members shift to semaglutide therapy → cardiovascular events decline across the book → hospital and specialty claims fall → medical care ratio improves
    What would break the call: GLP-1 utilization surges and pharmacy costs outrun avoided cardiac claims this year.
12. ▼ PFE Pfizer — impact -31 · confidence medium · horizon weeks · 2nd order
    Ozempic’s superior cardiovascular outcomes raise Pfizer’s efficacy benchmark, pressuring oral obesity pricing and increasing development costs.
    Chain: semaglutide sets cardiovascular efficacy standard → payers demand comparable outcomes from orals → Pfizer obesity program needs larger trials → development cost rises and pricing power falls
    What would break the call: Pfizer reports oral obesity data with a clean tolerability profile and rapid regulatory path.
13. ▲ CI Cigna — impact +31 · confidence medium · horizon quarters · 2nd order
    Superior cardiovascular outcomes lower Cigna’s medical costs by reducing complications among covered patients.
    Chain: covered lives shift to semaglutide → cardiac complications and admissions decline → Cigna medical claims expense falls → Express Scripts rebate volume rises
    What would break the call: Employers exclude GLP-1 coverage, cutting utilization and the associated rebate and outcomes benefit.
14. ▼ AMRN Amarin — impact -28 · confidence low · horizon quarters · 3rd order
    Amarin's Vascepa faces further crowding as cardiologists prioritize a therapy with broader metabolic and cardiovascular endpoints.
    Chain: semaglutide shows strong cardiovascular risk reduction → cardiologists prioritize incretin therapy first → residual risk agents lose prescribing attention → Vascepa volumes and pricing weaken
    What would break the call: Guidelines endorse icosapent ethyl as add-on therapy alongside GLP-1 treatment.
15. ▼ AMGN Amgen — impact -25 · confidence low · horizon quarters · 2nd order
    Amgen's MariTide program needs costly heart outcome data to win payer coverage against an established semaglutide standard.
    Chain: semaglutide becomes cardiovascular reference standard → payers require outcomes proof for MariTide → Amgen funds a large cardiovascular trial → launch timing slips and spend rises
    What would break the call: MariTide delivers best in class weight loss and durable dosing that payers reward immediately.
16. ▼ THC Tenet Healthcare — impact -25 · confidence low · horizon quarters · 3rd order
    Tenet Healthcare earnings decrease following lower volumes of cardiovascular surgeries from improved drug efficacy.
    Chain: population cardiac event rate declines → fewer cardiac admissions and surgeries → Tenet hospital and ambulatory volumes soften → procedure revenue growth slows
    What would break the call: Tenet's ambulatory surgery mix grows fast enough to offset declining cardiac admissions.
17. ▲ DXCM Dexcom — impact +25 · confidence low · horizon quarters · 3rd order
    Dexcom sensor sales volume increases with greater Ozempic prescriptions for diabetes patients overall.
    Chain: more diabetes patients start semaglutide → glucose monitoring supports dose titration → sensor prescriptions increase modestly → Dexcom unit volume rises
    What would break the call: Payers restrict continuous monitors for non-insulin patients, removing the attachment pathway.
18. ▲ TMO Thermo Fisher Scientific — impact +24 · confidence low · horizon quarters · 2nd order
    Thermo Fisher earns fill-finish and peptide manufacturing fees that scale with expanded semaglutide production runs for Novo.
    Chain: Novo expands semaglutide production volume → outsourced peptide and fill-finish demand rises → Thermo pharma services bookings increase → contract manufacturing revenue grows
    What would break the call: Novo keeps expanded fill-finish work in house at Catalent sites it owns.
19. ▲ VTRS Viatris — impact +22 · confidence low · horizon quarters · 3rd order
    Viatris targets generic semaglutide launches in unprotected markets, and stronger clinical standing raises the value of those copies.
    Chain: semaglutide gains best in class standing → patent expiry opens copies in several markets → Viatris launches generic semaglutide versions → generics revenue and margin improve
    What would break the call: Regulators delay generic semaglutide approvals or Novo wins extended patent protection abroad.
20. ▼ ISRG Intuitive Surgical — impact -20 · confidence low · horizon quarters · 3rd order
    Intuitive Surgical sees bariatric procedure volumes decline as stronger drug outcomes push patients away from weight loss surgery.
    Chain: stronger drug outcomes reduce surgery referrals → bariatric procedure volumes decline → fewer da Vinci bariatric cases performed → instrument and accessory revenue growth slows
    What would break the call: Post-GLP-1 body contouring and revision surgeries lift overall robotic procedure counts.
21. ▲ TEVA Teva — impact +20 · confidence low · horizon quarters
    Teva prepares generic semaglutide supply, so a molecule with proven heart benefits supports larger launch volumes later.
22. ▼ EW Edwards Lifesciences — impact -15 · confidence low · horizon quarters · 3rd order
    Edwards structural heart volumes depend on progressive cardiac disease, which broad semaglutide use slows over years.
    Chain: metabolic risk factors improve broadly → heart failure and valve disease progress slower → structural heart procedure growth moderates → Edwards revenue growth decelerates
    What would break the call: TAVR indication expansion into asymptomatic patients drives volume growth regardless of risk reduction.
23. ▼ MDT Medtronic — impact -15 · confidence low · horizon quarters
    Medtronic ships fewer stents and bariatric staplers as fewer patients progress to cardiac and surgical intervention.
24. ▲ BDX Becton Dickinson — impact +15 · confidence low · horizon quarters · 2nd order
    Becton Dickinson supplies pen needles and injection systems, so higher semaglutide dispensing lifts consumable unit shipments.
    Chain: semaglutide prescription volume rises → more pen needles consumed monthly → BD medical segment shipments increase → consumables revenue grows modestly
    What would break the call: Oral semaglutide adoption replaces injections and cuts pen needle demand.

What happened

More

Related scenarios

• Iranian Guards say two tankers hit mines in Hormuz
• PetroChina set for record trading profit as war upends markets
• Ascendis Pharma receives positive CHMP opinion for TransCon CNP
• ◇ What if… Bitcoin dips to $77,500 in October

Stocks in this scenario

NVO · LLY · VKTX · HIMS · GPCR · ELV · ALT · CVS · HCA · WST · UNH · PFE · CI · AMRN · AMGN · THC · DXCM · TMO · VTRS · ISRG · TEVA · EW · MDT · BDX · RMD

News events · All scenarios · Pricing · Track record · Methodology · Map your own scenario